T7	Exp 317 338	its structural analog
T8	Exp 256 260	that
T9	Exp 235 255	the antigen receptor
T10	Exp 278 305	the immunosuppressant FK506
T11	Exp 354 368	the other hand
T12	Exp 532 536	that
T13	Exp 537 541	both
T14	Exp 486 496	each other
T15	Exp 516 531	the possibility
T16	Exp 462 477	these two drugs
T17	Exp 617 619	We
T18	Exp 793 843	their effective biologic inhibitory concentrations
T19	Exp 625 629	that
T20	Exp 630 655	the dissociation constant
T21	Exp 672 702	the FK506 binding protein FKBP
T22	Exp 729 754	the dissociation constant
T23	Exp 1181 1204	The drug concentrations
T24	Exp 1249 1270	the relative affinity
T25	Exp 1274 1283	the drugs
T26	Exp 1295 1308	the abundance
T27	Exp 1313 1334	the immunophilin FKBP
T28	Exp 1481 1483	we
T29	Exp 1489 1493	that
T30	Exp 1368 1387	the interconversion
T31	Exp 1391 1398	the cis
T32	Exp 1422 1452	the peptidyl-prolyl amide bond
T33	Exp 1542 1563	the rotamase activity
T34	Exp 1683 1703	the biologic actions
T35	Exp 1707 1718	these drugs
T36	Exp 1587 1607	Neither FKBP binding
T37	Exp 1751 1755	that
T38	Exp 1859 1875	the immunophilin
T39	Exp 1728 1742	these findings
R5	Coref Anaphora:T8 Antecedent:T9
R6	Coref Anaphora:T7 Antecedent:T10
R7	Coref Anaphora:T12 Antecedent:T15
R8	Coref Anaphora:T18 Antecedent:T16
T1	Protein 370 383	interleukin 2
T2	Protein 385 389	IL-2
T3	Protein 926 930	IL-2
T4	Protein 1048 1052	IL-2
T5	Protein 1153 1157	IL-2
T6	Protein 1892 1896	IL-2
